Answers are grounded in this paper and cite their sources.
Retrospective trial evaluates adebrelimab plus TACE and HAIC efficacy in primary liver cancer, suggesting effective outcomes.
296 Background: This retrospective analysis reports on the use of adebrelimab—a novel PD-L1 inhibitor—in combination with transarterial chemoembolisation (TACE) and/or hepatic arterial infusion chemotherapy (HAIC) for the treatment of primary liver cancer. Methods: The study was approved by the Ethics Committee of the First Hospital of Jilin University and conducted within the interventional department. Inclusion criteria were: (1) pathological or clinical diagnosis of primary liver cancer; (2) at least one cycle of adebrelimab plus TACE and/or HAIC; (3) complete medical records and patient cooperation for follow-up. Cases were enrolled between March 2023 and January 2026. The primary endpoint was progression-free survival (PFS); secondary endpoints included overall response rate (ORR), disease control rate (DCR), overall survival (OS), and safety. Analyses were performed using R software (version 4.5.2). Results: Seventy-two patients were included. The cohort was predominantly male (83.3%), aged < 65 years (75.0%), with hepatitis B virus infection in 55.6%. Most patients had BCLC stage B disease (66.7%) and Child-Pugh class B liver function (59.7%); portal-vein tumour thrombus was present in 88.9%, and 19.4% had extrahepatic metastases. Median PFS was 7.1 months (95% CI 5.1–9.9 months). Median OS was 17.9 months (95% CI 10.8–not reached). ORR was 65.3% (47/72) and DCR was 70.8% (51/72). The most frequent any-grade adverse events (AEs) associated with interventional therapy (≥10%) were fever, hypoalbuminemia, and abnormal liver-function tests. Any-grade AEs attributed to adebrelimab included elevated bilirubin, increased creatinine, decreased white-blood-cell count, and fatigue. Grade ≥3 interventional-therapy-related AEs comprised elevated ALT (5.6%), elevated AST (15.3%), and raised blood bilirubin (2.8%). Grade ≥3 adebrelimab-related AEs were limited to decreased white-blood-cell count (1.4%). No fatal AEs were reported. Conclusions: The combination of adebrelimab with TACE and/or HAIC showed encouraging efficacy and a manageable safety profile in patients with primary liver cancer. Prospective clinical trials are warranted to further evaluate this regimen.
No takes yet. Share an insight, caveat, or question.
Zheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: